MAGNESIUM 1-GLYCEROPHOSPHATE

Details

Stereochemistry	RACEMIC
Molecular Formula	C3H7O6P.Mg
Molecular Weight	194.3628
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure of MAGNESIUM 1-GLYCEROPHOSPHATE

Structure Search

SMILES

[Mg++].OCC(O)COP([O-])([O-])=O

InChI

InChIKey=BHJKUVVFSKEBEX-UHFFFAOYSA-L

InChI=1S/C3H9O6P.Mg/c4-1-3(5)2-9-10(6,7)8;/h3-5H,1-2H2,(H2,6,7,8);/q;+2/p-2

HIDE SMILES / InChI

Molecular Formula	Mg
Molecular Weight	24.305
Charge	2
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C3H7O6P
Molecular Weight	170.0578
Charge	-2
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Description
Sources: https://www.nice.org.uk/guidance/esuom4/resources/preventing-recurrent-hypomagnesaemia-oral-magnesium-glycerophosphate-1503234975394501
Curator's Comment: description was created based on several sources, including: http://barnsleybest.nhs.sitekit.net/clinical-support/medicines/prescribing-guidelines/Oral%20Magnesium%20Supplementation%20for%20Hypomagnesaemia.pdf | http://base-donnees-publique.medicaments.gouv.fr/affichageDoc.php?specid=60240181&typedoc=N | http://www.isaltis.com/en/module/99999689/30/magnesium_glycerophosphate | http://eurekasante.vidal.fr/medicaments/vidal-famille/medicament-ouvima01-UVIMAG-B6.html

Magnesium glycerophosphate is a magnesium salt that is available as a tablet, capsule, liquid solution or liquid suspension for oral use. Magnesium glycerophosphate is a bioavailable well tolerated source of magnesium. The organic glycerophosphoric anion, by itself, offers very significant nutritional advantages (a source of phosphorus, permeation enhancer). Adverse effects are: diarrhea, abdominal pain.

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
magnesium ion homeostasis 70 Target ID: GO:0010960 Sources: http://www.isaltis.com/en/module/99999689/30/magnesium_glycerophosphate	Modulator 846

Conditions

Condition	Modality	Targets	Highest Phase	Product
Hypomagnesemia 3 Sources: http://barnsleybest.nhs.sitekit.net/clinical-support/medicines/prescribing-guidelines/Oral%20Magnesium%20Supplementation%20for%20Hypomagnesaemia.pdf https://www.nice.org.uk/guidance/esuom4/resources/preventing-recurrent-hypomagnesaemia-oral-magnesium-glycerophosphate-1503234975394501	Curative		Approved 8583	UVIMAG B6 Approved Use Indicated for the treatment of magnesium deficiencies.

PubMed

Title	Date	PubMed
Generation of composites for bone tissue-engineering applications consisting of gellan gum hydrogels mineralized with calcium and magnesium phosphate phases by enzymatic means.	2016-11	24616374
Development of thermosensitive hydrogels of chitosan, sodium and magnesium glycerophosphate for bone regeneration applications.	2015-04-09	25859630
A case of hypomagnesaemia due to malabsorption, unresponsive to oral administration of magnesium glycerophosphate, but responsive to oral magnesium oxide supplementation.	2001-06	11358909
The effect of magnesium oral therapy on spasticity in a patient with multiple sclerosis.	2000-11	11136367
Oral magnesium reduces ventricular ectopy in digitalised patients with chronic atrial fibrillation.	1990	1692533

Patents

Sample Use Guides

In Vivo Use Guide

1-2 tablets three to four times daily (12-32 mmol/day)

Route of Administration: Oral

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:18:05 GMT 2025` Edited by `admin` on `Mon Mar 31 18:18:05 GMT 2025`
Record UNII	89I3KNZ71G
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

MAGNESIUM 1-GLYCEROPHOSPHATE

Common Name

English

ANHYDROUS MAGNESIUM GLYCEROPHOSPHATE

Preferred Name

English

RAC-GLYCERO-1-PHOSPHATE, MAGNESIUM SALT

Common Name

English

GLYCEROL, 1-(DIHYDROGEN PHOSPHATE), MAGNESIUM SALT (1:1)

Common Name

English

Code System Code Type Description

EPA CompTox

DTXSID00919002